Setipiprant

Summary

Setipiprant (CHEMBL2386081) is a phase-3 clinical-stage small molecule targeting PTGDR2; indicated across 3 conditions including seasonal allergic rhinitis and alopecia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 1 (PTGDR2)
• Indications: 3 conditions
• Clinical trials: 5
• Chemistry: 402.4 Da · C24H19FN2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2386081
Name	Setipiprant
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	49843471
Molecular formula	C24H19FN2O3
Molecular weight	402.4
InChIKey	IHAXLPDVOWLUOS-UHFFFAOYSA-N

SMILES: C1CN(CC2=C1N(C3=C2C=C(C=C3)F)CC(=O)O)C(=O)C4=CC=CC5=CC=CC=C54

IUPAC name: 2-[8-fluoro-2-(naphthalene-1-carbonyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5-yl]acetic acid

Also known as: ACT-129968, KYTH-105, Setipiprant, SETIPIPRANT

Patent coverage: 55 distinct patent families (226 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 203 (90%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
PTGDR2	DP2 receptor	Antagonist	8.22	0%	Q9Y5Y4

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Prostaglandin E2 receptor EP2 subtype, Prostaglandin D2 receptor, Prostaglandin D2 receptor 2.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PTGDR2	8.22	IC50	6	nM	CHEMBL_ACT_13318059
PTGDR2	7.52	IC50	30	nM	CHEMBL_ACT_13316397
PTGDR2	7.1	IC50	80	nM	CHEMBL_ACT_13316329
PTGDR2	6.63	IC50	235	nM	CHEMBL_ACT_13316265
PTGDR2	6.47	IC50	340	nM	CHEMBL_ACT_13316258
PTGDR	5.89	IC50	1290	nM	CHEMBL_ACT_13316231
PTGER2	5.58	IC50	2600	nM	CHEMBL_ACT_13316224

Target pathways

Aggregated over 1 target gene(s): PTGDR2.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Prostanoid ligand receptors	1	PTGDR2
G alpha (i) signalling events	1	PTGDR2

Dominant GO biological processes

GO term	Targets
chemotaxis	1
immune response	1
G protein-coupled receptor signaling pathway	1
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	1
neuropeptide signaling pathway	1
calcium-mediated signaling	1
positive regulation of G protein-coupled receptor signaling pathway	1
cellular response to prostaglandin D stimulus	1
negative regulation of male germ cell proliferation	1
signal transduction	1

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
seasonal allergic rhinitis	3	MONDO:0005324	EFO:0003956
alopecia	2	MONDO:0004907	MONDO:0004907
asthma	2	MONDO:0004979	MONDO:0004979

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2	3
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01484119	PHASE3	COMPLETED	Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis
NCT01225315	PHASE2	COMPLETED	Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma
NCT01241214	PHASE2	COMPLETED	Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis
NCT02781311	PHASE2	COMPLETED	A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males
NCT02381496	PHASE1	COMPLETED	A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

10 molecules share ≥1 primary target. Top 10 by shared-target count:

Molecule	Source	Status	Shared targets
INDOMETHACIN	ChEMBL + PubChem	Phase 4 (approved)	PTGDR2
LAROPIPRANT	ChEMBL	Phase 4 (approved)	PTGDR2
RAMATROBAN	ChEMBL	Phase 4 (approved)	PTGDR2
FEVIPIPRANT	ChEMBL	Phase 3	PTGDR2
TIMAPIPRANT	ChEMBL	Phase 3	PTGDR2
AZD1981	ChEMBL	Phase 2	PTGDR2
BI-671800	ChEMBL	Phase 2	PTGDR2
FENTIAZAC	ChEMBL	Phase 2	PTGDR2
QAV680	ChEMBL	Phase 2	PTGDR2
VIDUPIPRANT	ChEMBL	Phase 2	PTGDR2